
    
      All patients who fulfill all eligibility criteria will undergo a leukapheresis procedure. All
      eligible/enrolled patients will receive standard-of-care therapy with carboplatin/gemcitabine
      or carboplatin/paclitaxel starting 2 to 7 days after leukapheresis.

      After 6 cycles of chemotherapy, patients will start maintenance treatment with DCVAC/OvCa.

      Treatment will continue irrespective of tumor progression until completion, refusal,
      intolerance of treatment or death.
    
  